We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The drug “represents an important new option for the acute treatment of migraine,” according to Billy Dunn, acting director of CDER’s Office of Neuroscience. Read More
Following two previous years of significant increases the agency is no longer “running on fumes” according to the Alliance for a Stronger FDA. Read More
The FDA is taking issue with a new study that says the agency can’t tell if its risk evaluation and mitigation strategy (REMS) program for extended-release and long-acting opioids is effective. Read More
“By providing comprehensive, accessible learning tools, we will support outsourcing facilities in reliably producing high-quality compounded products that meet FDA’s standards,” said CDER Director Janet Woodcock. Read More